MAP2K7 and breast carcinoma: These results raise the possibility that tumor cells in breast cancer patients will exhibit differential sensitivities to therapies that target EGF receptor family members and therapies against alternative signaling pathways, such as integrin β1-ILK might be an effective target in a subgroup of triple negative breast cancer (TNBC) that exhibit resistance against MEK inhibition.